Apr 5, 2021 3:30pm Inscripta’s latest funding round will support the development and distribution of its Onyx benchtop platform, which uses CRISPR gene editing technology for fully automated genomic engineering. (AstraZeneca) Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses. The genomic engineering company, a member of Fierce Medtech’s 2019 Fierce 15, recently closed a series E funding round totaling $150 million. The investment was led by Fidelity Management and Research Company and funds and accounts managed by T. Rowe Price Associates. Upon the close of a $125 million series D round in December 2019, Inscripta calculated its total amount of funds raised since its 2015 founding at $259.5 million. With the latest influx of funds and an extension of the series D in November 2020, that total now clocks in at well over $450 million.